Author

C. Cannata

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell signaling & trafficking· 2 Organism:human· 2 Approach:statistical model· 2 Assay:ATAC-seq· 1 Research Focus:benchmarking· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

D. Datta· 2 shared L. Espinar· 2 shared S. Sdelci· 2 shared A. Ganez Zapater· 1 shared A. Ganez-Zapater· 1 shared A. Janic· 1 shared A. Miro Canturri· 1 shared A. Ragas· 1 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. Datta

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Adaptation to ARF6-depletion in KRAS-driven PDAC is abolished by targeting TLR2

R. Ghose, S. Das, J. Urgel-Solas, F. Pezzano, D. Datta, U. Ghose, A. Ganez-Zapater, N. Pardo-Lorente, L. Espinar, L. Garcia, C. Cannata, V. Ruprecht, A. Janic, S. Sdelci

This study identifies TLR2 as a target to counteract adaptation to ARF6 depletion in KRAS-driven PDAC, reducing proliferation, migration, and invasion.

bioRxiv · Nov 30, 2023 · PreprintCancer Biology

Defining the data gap: what do we know about environmental exposure, hazards and risks of pharmaceuticals in the European aquatic environment?

F. D. Spilsbury, P. A. Inostroza, P. Svedberg, C. Cannata, A. Ragas, T. Backhaus

This study identifies significant data gaps in monitoring and ecotoxicity data for pharmaceuticals in European waterways, highlighting 68 APIs for monitoring and 66 for ecotoxicity testing.

bioRxiv · Jul 10, 2023Pharmacology & Toxicology

The BRD4S-LOXL2-MED1 interaction at the forefront of cell cycle transcriptional control in triple-negative breast cancer

L. Pascual-Reguant, T. V. Tian, D. Datta, D. Cianferoni, S. Kourtis, A. Ganez Zapater, C. Cannata, Q. Serra Camprubi, L. Espinar, M. Guirola, J. Querol, A. Miro Canturri, J. Arribas, L. Serrano, S. Peiro, S. Sdelci

This study shows that inhibiting LOXL2 and BRD4 together reduces triple-negative breast cancer proliferation by disrupting the BRD4S-LOXL2-MED1 interaction that controls cell cycle gene expression.

bioRxiv · May 27, 2022 · PreprintCancer Biology